CoChat

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease

Gabani, Mohanad, Shapiro, Michael D, Toth, Peter P · 2023 · European Cardiology Review
Cited by 33

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the world’s leading cause of death. ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia, hypertension, diabetes and heightened systemic inflammatory tone, among others. LDL cholesterol is one of the most well-studied and established mediators targeted for primary and secondary prevention of ASCVD. However, despite the strength of evidence supporting LDL cholesterol reduction by multiple management strategies, ASCVD events can still recur, even in patients whose LDL cholesterol has been very aggressively reduced. Hypertriglyceridaemia and elevated levels of triglyceride-rich lipoproteins (TRLs) may be key contributors to ASCVD residual risk. Several observational and genetic epidemiological studies have highlighted the causal role of triglycerides within the TRLs and/or their remnant cholesterol in the development and progression of ASCVD. TRLs consist of intestinally derived chylomicrons and hepatically synthesised very LDL. Lifestyle modification has been considered the first line intervention for managing hypertriglyceridaemia. Multiple novel targeted therapies are in development, and have shown efficacy in the preclinical and clinical phases of study in managing hypertriglyceridaemia and elevated TRLs. This comprehensive review provides an overview of the biology, pathogenicity, epidemiology, and genetics of triglycerides and TRLs, and how they impact the risk for ASCVD. In addition, we provide a summary of currently available and novel emerging triglyceride-lowering therapies in development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15420/ecr.2023.16

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1: Exogenous Pathway (Chylomicron Biosynthesis): The Biosynthesis of Chylomicrons Begins as a Response to Dietary Fat Intake by Jejunal Enterocytes
Figure 1: Exogenous Pathway (Chylomicron Biosynthesis): The Biosynthesis of Chylomicrons Begins as a Response to Dietary Fat Intake by Jejunal EnterocytesCC BY-NC · PubMed Central
Figure 2: The Endogenous Pathway (Very LDL Biosynthesis)
Figure 2: The Endogenous Pathway (Very LDL Biosynthesis)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 70

  1. Rosenson RS, Shaik A, Song W. New therapies for lowering triglyceride-rich lipoproteins: JACC focus Seminar 3/4. J Am Coll Cardiol 2021;78:1817–30. https://doi.org/10.1016/j.jacc.2021.08.051; PMID: 34711341. · DOI · Paper page
  2. Jarcho JA, Keaney Jr JF. Proof that lower is better – LDL cholesterol and IMPROVE-IT. N Engl J Med 2015;372:2448–50. https://doi.org/10.1056/NEJMe1507041; PMID: 26039520. · DOI · Paper page
  3. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345–61. https://doi.org/10.1093/eurheartj/ehr112; PMID: 21531743. · DOI
  4. Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011;301:E429–46. https://doi.org/10.1152/ajpendo.00178.2011; PMID: 21693689. · DOI · Paper page
  5. Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 2014;25:35–9. https://doi.org/10.1097/MOL.0000000000000040; PMID: 24345989. · DOI · Paper page
  6. Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998;27:503–19. https://doi.org/10.1016/s0889-8529(05)70023-2; PMID: 9785050. · DOI · Paper page
  7. Goldstein JL, Ho YK, Brown MS, et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem 1980;255:1839–48. https://doi.org/10.1016/S0021-9258(19)85958-6; PMID: 7354064. · DOI · Paper page
  8. Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160–6. https://doi.org/10.1161/ATVBAHA.110.215434; PMID: 21030716. · DOI · Paper page
  9. Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol 2013;4:127. https://doi.org/10.3389/fphar.2013.00127; PMID: 24109453. · DOI · Paper page
  10. Alipour A, van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792–7. https://doi.org/10.1161/ATVBAHA.107.159749; PMID: 18218988. · DOI · Paper page
  11. Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007;48:1673–80. https://doi.org/10.1194/jlr.R700001-JLR200; PMID: 17496332. · DOI · Paper page
  12. Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis 2009;8:3. https://doi.org/10.1186/1476-511X-8-3; PMID: 19196457. · DOI
  13. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013;9:617–70. https://doi.org/10.2147/VHRM.S37119; PMID: 24174878. · DOI
  14. Mailly F, Tugrul Y, Reymer PW, et al. A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1995;15:468–78. https://doi.org/10.1161/01.atv.15.4.468; PMID: 7749858. · DOI · Paper page
  15. Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996;94:1913–8. https://doi.org/10.1161/01.cir.94.8.1913; PMID: 8873668. · DOI · Paper page
  16. Liu X, Li J, Liao J, et al. Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr(-/-) mice. Atherosclerosis 2019;282:100–9. https://doi.org/10.1016/j.atherosclerosis.2019.01.025; PMID: 30721842. · DOI
  17. Wulff AB, Nordestgaard BG, Tybjærg-Hansen A. APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol 2018;38:660–8. https://doi.org/10.1161/ATVBAHA.117.310473; PMID: 29348120. · DOI · Paper page
  18. Liu Y, Xu J, Tao W, et al. A compound heterozygous mutation of lipase maturation Factor 1 is responsible for hypertriglyceridemia of a patient. J Atheroscler Thromb 2019;26:136–44. https://doi.org/10.5551/jat.44537; PMID: 29910226. · DOI
  19. Varbo A, Benn M, Tybjærg-Hansen A, et al. TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol 2011;31:451–7. https://doi.org/10.1161/ATVBAHA.110.216333; PMID: 21071687. · DOI · Paper page
  20. Zannis VI. Genetic polymorphism in human apolipoprotein E. Methods Enzymol 1986;128:823–51. https://doi.org/10.1016/0076-6879(86)28109-4; PMID: 3724530. · DOI
  21. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001;154:529–37. https://doi.org/10.1016/s0021-9150(00)00570-0; PMID: 11257253. · DOI · Paper page
  22. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917–23. https://doi.org/10.1172/JCI118751; PMID: 8675707. · DOI · Paper page
  23. Gómez P, Miranda JL, Marín C, et al. Influence of the −514C/T polymorphism in the promoter of the hepatic lipase gene on postprandial lipoprotein metabolism. Atherosclerosis 2004;174:73–9. https://doi.org/10.1016/j.atherosclerosis.2003.12.038; PMID: 15135253. · DOI
  24. Zambon A, Deeb SS, Pauletto P, et al. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol 2003;14:179–89. https://doi.org/10.1097/00041433-200304000-00010; PMID: 12642787. · DOI · Paper page
  25. Stanford KI, Wang L, Castagnola J, et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem 2010;285:286–94. https://doi.org/10.1074/jbc.M109.063701; PMID: 19889634. · DOI · Paper page
  26. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762–70. https://doi.org/10.1161/01.cir.88.6.2762; PMID: 8252689. · DOI · Paper page
  27. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001;154:229–36. https://doi.org/10.1016/s0021-9150(00)00484-6; PMID: 11137104. · DOI · Paper page
  28. Imke C, Rodriguez BL, Grove JS, et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb Vasc Biol 2005;25:1718–22. https://doi.org/10.1161/01.ATV.0000173310.85845.7b; PMID: 15947240. · DOI · Paper page
  29. Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015;116:665–73. https://doi.org/10.1161/CIRCRESAHA.116.304846; PMID: 25411050. · DOI · Paper page
  30. Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem 2015;61:533–43. https://doi.org/10.1373/clinchem.2014.234146; PMID: 25605681. · DOI · Paper page
  31. Saeed A, Feofanova EV, Yu B, et al. Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease. J Am Coll Cardiol 2018;72:156–69. https://doi.org/10.1016/j.jacc.2018.04.050; PMID: 29976289. · DOI · Paper page
  32. Wadström BN, Wulff AB, Pedersen KM, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J 2022;43:3258–69. https://doi.org/10.1093/eurheartj/ehab705; PMID: 34661640. · DOI · Paper page
  33. Chevli PA, Islam T, Pokharel Y, et al. Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Lipidol 2022;16:870–7. https://doi.org/10.1016/j.jacl.2022.09.005; PMID: 36180367. · DOI
  34. Huh JH, Han KD, Cho YK, et al. Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study. Cardiovasc Diabetol 2022;21:228. https://doi.org/10.1186/s12933-022-01667-6; PMID: 36324177. · DOI · Paper page
  35. Yoshida H, Ito K, Manita D, et al. Clinical significance of intermediate-density lipoprotein cholesterol determination as a predictor for coronary heart disease risk in middle-aged men. Front Cardiovasc Med 2021;8:756057. https://doi.org/10.3389/fcvm.2021.756057; PMID: 34881308. · DOI
  36. Yang N, Wang M, Liu J, et al. The level of remnant cholesterol and implications for lipid-lowering strategy in hospitalized patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-acute coronary syndrome project. Metabolites 2022;12:898. https://doi.org/10.3390/metabo12100898; PMID: 36295800. · DOI
  37. Varbo A, Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur Heart J 2021;42:4833–43. https://doi.org/10.1093/eurheartj/ehab293; PMID: 34023898. · DOI · Paper page
  38. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol 2014;8:473–88. https://doi.org/10.1016/j.jacl.2014.07.007; PMID: 25234560. · DOI · Paper page
  39. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45. https://doi.org/10.1056/NEJM198711123172001; PMID: 3313041. · DOI · Paper page
  40. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999;341:410–8. https://doi.org/10.1056/NEJM199908053410604; PMID: 10438259. · DOI · Paper page
  41. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042–51. https://doi.org/10.1124/jpet.301.3.1042; PMID: 12023536. · DOI · Paper page
  42. Larsen ML, Illingworth DR, O’Malley JP. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis 1994;106:235–40. https://doi.org/10.1016/0021-9150(94)90128-7; PMID: 8060383. · DOI
  43. Syvänne M, Vuorinen-Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13:286–95. https://doi.org/10.1161/01.atv.13.2.286; PMID: 8427863. · DOI · Paper page
  44. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21–7. https://doi.org/10.1161/01.cir.102.1.21; PMID: 10880410. · DOI · Paper page
  45. Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59:181–9. https://doi.org/10.1016/s0168-8227(02)00243-7; PMID: 12590014. · DOI
  46. Ohno Y, Miyoshi T, Noda Y, et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol 2014;13:71. https://doi.org/10.1186/1475-2840-13-71; PMID: 24708775. · DOI
  47. Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278–85. https://doi.org/10.5551/jat.11.278; PMID: 15557710. · DOI · Paper page
  48. Min YJ, Choi YH, Hyeon CW, et al. Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. Korean Circ J 2012;42:741–6. https://doi.org/10.4070/kcj.2012.42.11.741; PMID: 23236325. · DOI
  49. Sano K, Nakamura T, Hirano M, et al. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010;74:1644–50. https://doi.org/10.1253/circj.cj-10-0079; PMID: 20574136. · DOI
  50. Blair HA, Dhillon S. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs 2014;14:393–400. https://doi.org/10.1007/s40256-014-0090-3; PMID: 25234378. · DOI
  51. Innes JK, Calder PC. Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: an update for 2020. Int J Mol Sci 2020;21:1362. https://doi.org/10.3390/ijms21041362; PMID: 32085487. · DOI · Paper page
  52. Myran L, Nguyen TN. Icosapent ethyl (Vascepa) for hyperlipidemia/hypercholesterolemia to reduce risk of heart attack and stroke. Am Fam Phys 2021;103:117–8. PMID: 33448769.
  53. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:2268–80. https://doi.org/10.1001/jama.2020.22258; PMID: 33190147. · DOI · Paper page
  54. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–84. https://doi.org/10.1681/ASN.V10102177; PMID: 10505695. · DOI · Paper page
  55. Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR-α agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs 2017;26:593–602. https://doi.org/10.1080/13543784.2017.1312339; PMID: 28343425. · DOI · Paper page
  56. Yamashita S, Arai H, Yokote K, et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol 2018;12:1267-79.e4. https://doi.org/10.1016/j.jacl.2018.06.010; PMID: 30077640. · DOI · Paper page
  57. Rosenson RS, Rader D, Ali S, et al. Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia. Atherosclerosis 2022;355:223. https://doi.org/10.1016/j.atherosclerosis.2022.06.874. · DOI
  58. Paik J, Duggan S. Volanesorsen: first global approval. Drugs 2019;79:1349–54. https://doi.org/10.1007/s40265-019-01168-z; PMID: 31301033. · DOI · Paper page
  59. Blom DJ, O’Dea L, Digenio A, et al. Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol 2018;12:1234–1243.e5. https://doi.org/10.1016/j.jacl.2018.05.013; PMID: 30318066. · DOI · Paper page
  60. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022;43:1401–12. https://doi.org/10.1093/eurheartj/ehab820; PMID: 35025993. · DOI · Paper page
  61. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40–6. https://doi.org/10.1016/S0140-6736(12)61731-0; PMID: 23122768. · DOI · Paper page
  62. Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 long-term extension study. J Atheroscler Thromb 2019;26:368–77. https://doi.org/10.5551/jat.45708; PMID: 30259883. · DOI
  63. Marais AD. Apolipoprotein E and atherosclerosis. Curr Atheroscler Rep 2021;23:34. https://doi.org/10.1007/s11883-021-00933-4; PMID: 33970359. · DOI
  64. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, et al. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997;99:1606–13. https://doi.org/10.1172/JCI119323; PMID: 9120004. · DOI · Paper page
  65. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012;272:185–96. https://doi.org/10.1111/j.1365-2796.2012.02516.x; PMID: 22239554. · DOI · Paper page
  66. Davison PJ, Stalenhoef AF, Humphries SE. Apolipoprotein CII (apo CII) gene expression defect in an individual with familial apo CII deficiency. Biochem Biophys Res Commun 1987;148:320–8. https://doi.org/10.1016/0006-291x(87)91113-2; PMID: 2445343. · doi:10.1016/0006-291x(87)91113-2
  67. Gerber Y, Goldbourt U, Cohen H, Harats D. Association between serum apolipoprotein C(II) concentration and coronary heart disease. Prev Med 2002;35:42–7. https://doi.org/10.1006/pmed.2002.1045; PMID: 12079439. · DOI
  68. Jiao X, Yang Y, Li L, et al. Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE-/- mice(-/). Atherosclerosis 2020;307:63–71. https://doi.org/10.1016/j.atherosclerosis.2020.06.014; PMID: 32739681. · DOI
  69. Voyvodic PL, Min D, Liu R, et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem 2014;289:9547–59. https://doi.org/10.1074/jbc.M113.541573; PMID: 24554698. · DOI
  70. Mabuchi H, Nohara A, Inazu A. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Mol Cells 2014;37:777–84. https://doi.org/10.14348/molcells.2014.0265; PMID: 25410905. · DOI

Cited by

See all 33

Metadata

Authors
Gabani, M., Shapiro, M. D., & Toth, P. P.
Affiliations
  • Division of Cardiology, Wake Forest Baptist Health, Winston-Salem, North Carolina, US
  • CGH Medical Center, Sterling, Illinois, US; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, US
Venue
European Cardiology Review
Published
2023-09-28
Volume
18
ISSN
  • 1758-3764
  • 1758-3756
Cited by
33
References
52
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.